Grail, a genetic sequencing giant that has financed more than $2 billion in cancer diagnosis, has applied for a listing.

On September 10th Grail, a US cancer sieve company, raised its offer to the US Securities and Exchange Commission to list on NASDAQ, potentially raising as much as $100m.
Grail was founded in 2016 by genetic sequencing giant Illumina to develop cancer screening and testing technologies.
comes after Grail released data showing that its liquid biopsy tests were able to detect more than 50 different types of diseases, using a single blood sample that identified specific organs where 93 percent of tumors grew.
, it has completed four rounds of financing totaling more than $2,115 million.
May, it had just received $390 million in round D financing.
the investors behind it, including Johnson and Johnson, ARCH Venture Partner, Sutter Hill Ventur, Bezos Expeditions, and others.
14.6 per cent of Grail before the initial public offering, illumina was its largest single shareholder.
the two companies have signed a decade-long supply and commercialization agreement.
According to its prospectos, Grail plans to launch a commercial cancer screening test called Gallei in 2021, which will be developed in a laboratory-developed manner before seeking full FDA approval, and estimates that its early screening technology will detect nearly 70 percent of fatal cancers within five years.
at Harvard University and the University of Toronto believe grail's claim that most cancers can be prevented is based on data models rather than practical experience.
clearly, Grail is targeting cancer screening for the general population.
combined Illumina's gene sequencing technology with the latest data science to collect data on about 115,000 people at a cost of more than $1 billion.
grail said it was the largest genomic and clinical data set in the field of cancer.
previously, specific cancer detection methods for high-risk groups, such as breast cancer X-rays, cervical cancer Pap tests and PSA prostate cancer blood tests, were not uncommon.
, Exact Sciences has achieved early screening for colon cancer through Cologuard products.
currently, Grail does not have products or revenue.
said it lost $136.4 million in the first half of 2020 and had no revenue, according to its prospecto.
a loss of $117.2 million, or more than 16 percent, a year earlier, mainly due to research and development costs, including technology development and clinical research.
with Grail's launch, it will also compete directly with a number of listed companies in the field of cancer diagnosis, including Biocept, Burning Rock Biotech, Epigenomics, Exact Sciences, Guardant Health, Genetron Holdings, NeoGenomics, Personalis and others.
the secret plex Source: !-- content presentation ends -- !-- to determine whether the login ends.